HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort

Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer

(2014) C. Ferrario et al.   JOURNAL OF CHEMOTHERAPY

Management of small HER2 overexpressing tumours

(2012) Arnoud Templeton et al.   BREAST CANCER RESEARCH AND TREATMENT

Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers

(2012) Rita Nahta et al.   BREAST CANCER RESEARCH AND TREATMENT

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

(2011) C. M. Kelly et al.   ANNALS OF ONCOLOGY

Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas

(2011) M. J. Rodrigues et al.   ANNALS OF ONCOLOGY

Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer

(2011) Lorenzo Livi et al.   CANCER

Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer

(2011) Ana P. Kiess et al.   CANCER

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

(2011) Heather L. McArthur et al.   CANCER

Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype

(2011) Rachel L. Theriault et al.   Clinical Breast Cancer

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

(2011) Emiel Rutgers et al.   EUROPEAN JOURNAL OF CANCER

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer

(2011) Kazuhiro Araki et al.   Breast Cancer

Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment?

(2010) M. Joerger et al.   ANNALS OF ONCOLOGY

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature

(2010) M Knauer et al.   BRITISH JOURNAL OF CANCER

Trastuzumab Treatment in T1ab, Node-Negative, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Carcinomas

(2010) Manuel Jorge Rodrigues et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

(2009) Yeon Hee Park et al.   BREAST CANCER RESEARCH AND TREATMENT

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

(2009) S M Tovey et al.   BRITISH JOURNAL OF CANCER

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial

(2009) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)

(2008) Hiroaki Nitta et al.   Diagnostic Pathology

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2008) I. J. Dahabreh et al.   ONCOLOGIST

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY